CoreOneLabs_LOGO_COL_LRG_300dpi.png
Core One Labs’ Successful Patent Application Filing for Protection of its Biosynthetic Production System for Psilocybin Marks a Significant Milestone for the Progression of Psychedelic Health Care
09 févr. 2022 03h00 HE | Core One Labs Inc.
VANCOUVER, British Columbia, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core One”) is pleased to announce that...
CoreOneLabs_LOGO_COL_LRG_300dpi.png
Core One Labs’ Akome Seeks to Revolutionize Treatment of Parkinson’s Disease and Submits Application to Protect IP
26 juil. 2021 07h00 HE | Core One Labs Inc.
VANCOUVER, British Columbia, July 26, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABD), (Frankfurt: LD6, WKN: A3CSSU) (the “Company”) is pleased to announce that its wholly...
CoreOneLabs_LOGO_COL_LRG_300dpi.png
Core One Labs’ Akome Biotech Protects New AKO003 Ketamine-Based Breakthrough Drug Formulation For Depression Treatment
21 juil. 2021 03h00 HE | Core One Labs Inc.
VANCOUVER, British Columbia, July 21, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL) (OTC: CLABD) (Frankfurt: LD6, WKN:A3CSSU) (the “Company”) is excited to announce that its wholly owned...
CoreOneLabs_LOGO_COL_LRG_300dpi.png
REPEAT - New Psychedelic Drug Formula Believed to Work to Mitigate Neurological Damage Due to Stroke, Provisional Patent Application Filed
21 juin 2021 09h15 HE | Core One Labs Inc.
VANCOUVER, British Columbia, June 21, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company”) is pleased to announce that its wholly...
CoreOneLabs_LOGO_COL_LRG_300dpi.png
New Psychedelic Drug Formula Believed to Work to Mitigate Neurological Damage Due to Stroke, Provisional Patent Application Filed
19 juin 2021 18h30 HE | Core One Labs Inc.
VANCOUVER, British Columbia, June 19, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company”) is pleased to announce that its wholly...
CoreOneLabs_LOGO_COL_LRG_300dpi.png
REPEAT – Core One Labs Commences Development on Patent Pending Psychedelic Drug Formulation for the Treatment of Alzheimer’s Disease
06 mai 2021 09h00 HE | Core One Labs Inc.
VANCOUVER, British Columbia, May 06, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company” or “Core One”) is pleased to announce that...
CoreOneLabs_LOGO_COL_LRG_300dpi.png
Core One Labs Commences Development on Patent Pending Psychedelic Drug Formulation for the Treatment of Alzheimer’s Disease
06 mai 2021 03h10 HE | Core One Labs Inc.
VANCOUVER, British Columbia, May 06, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company” or “Core One”) is pleased to announce that...
CoreOneLabs_LOGO_COL_LRG_300dpi.png
REPEAT - Core One Labs Completes Milestone Acquisition of Akome Biotech
04 mai 2021 09h00 HE | Core One Labs Inc.
VANCOUVER, British Columbia, May 04, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company” or “Core One”) a biotechnology research and...
CoreOneLabs_LOGO_COL_LRG_300dpi.png
Core One Labs Completes Milestone Acquisition of Akome Biotech
04 mai 2021 03h10 HE | Core One Labs Inc.
VANCOUVER, British Columbia, May 04, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company” or “Core One”) a biotechnology research and...
CoreOneLabs_LOGO_COL_LRG_300dpi.png
REPEAT -- Core One Labs Reaches Definitive Agreement to Acquire Akome Biotech
29 avr. 2021 09h00 HE | Core One Labs Inc.
VANCOUVER, British Columbia, April 29, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company”), a biotechnology research and development...